Full-Time

Vice President Investment Decisions Rare Disease

Investment Decisions, Rare Disease

Deadline 9/21/26
Alexion

Alexion

5,001-10,000 employees

Global biopharmaceuticals focusing on rare diseases

No salary listed

Dublin, Ireland

In Person

Based in Ireland; relocation to Dublin considered.

Category
Biology & Biotech (1)
Required Skills
Financial Modeling

Get referred to Alexion

See people who can refer or advise you

Requirements
  • Advanced degree in Business, Life Sciences, or a related discipline; MD, PhD, MBA, or equivalent strongly preferred
  • Over 15 years of experience
  • Significant strategic leadership experience in the biopharmaceutical or life sciences sector, including VP-level or equivalent responsibility
  • Deep expertise in portfolio investment analysis and business case development across R&D and/or commercial programs
  • Strong track record of advising senior executive and C-suite leaders on strategic investment decisions in a complex, matrixed environment
  • Experience in drug discovery and development and in shaping decisions that maximise portfolio and intellectual property value
  • Strong understanding of corporate governance, Board reporting, and strategic planning
  • Excellent analytical, communication, and influencing skills, with the ability to translate complex issues into clear and actionable recommendations
  • Ability to work effectively across multiple functions, senior stakeholders, and governance forums
  • Enterprise leadership capability, with a collaborative style and the ability to challenge constructively
  • Demonstrated commitment to diversity, inclusion, and values-based leadership
  • Based in Ireland or willing to relocate to Dublin
Responsibilities
  • Support Rare Disease therapeutic area strategy in partnership with the VP R&D and senior Alexion leaders
  • Lead investment governance and business case quality across key decision-making forums, including ESPC, LSPC, rDRC, and FRC
  • Develop and maintain decision-support frameworks for the CEO and ALT, ensuring business cases are robust, assumptions are challenged, and scenarios are appropriately stress-tested
  • Advise on long-term strategy, portfolio investment sizing, and business development or partnership opportunities, translating strategic priorities into clear financial and planning frameworks
  • Support Irish entity governance for APIO and AZIL, including Board engagement, compliance with Irish legal and regulatory obligations, and alignment with governance and reporting requirements
  • Manage key government and fiscal relationships in Ireland, including external agencies and strategic partners, as relevant to the role
  • Contribute to strategic investment, prioritisation, acceleration, reprioritisation, and termination decisions across the Rare Disease portfolio
  • Continuously assess opportunities to enhance the value of existing assets and intellectual property, including recommendations in emerging or strategically important areas
  • Act as a senior escalation point for Rare Disease R&D risks and issues, determining the appropriate course of action and raising matters to the CEO as needed
  • Represent the organisation’s values and leadership expectations in all aspects of the role
  • Optional Responsibilities: AI and Data Innovation, to enhance speed, efficiency, and decision-making across the business and portfolio
  • Optional Responsibilities: Translational Medicine, to improve success rates, strengthen development decisions, and increase portfolio value

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ALXN2220 Phase 3 success in ATTR-CM addresses $500M+ peak sales opportunity with no approved amyloid-depleting competitor.
  • VOYDEYA and Ultomiris label expansions capture previously untreated patient subsets, extending core franchise revenue streams.
  • LogicBio acquisition expands genomic medicine pipeline, diversifying beyond complement-mediated disorders into gene therapy markets.

What critics are saying

  • Soliris/Ultomiris biosimilar entry 2026–2027 erodes $6B+ annual revenue; patent cliff creates 40–60% revenue cliff post-2028.
  • ALXN2220 Phase 3 failure eliminates $500M+ opportunity; cardiac safety signals halt program in 18–30 months.
  • Complement inhibitor commoditization: five rival C3/C5/Factor D inhibitors compress pricing 15–25% by 2027, fragmenting PNH franchise.

What makes Alexion unique

  • Pioneering complement cascade expertise translates into first-mover advantage across PNH, aHUS, NMOSD rare indications.
  • Integrated AstraZeneca scale enables global commercialization and manufacturing capabilities unmatched by pure-play biotech competitors.
  • Patient-centric clinical trial design with real-world evidence frameworks addresses rare disease regulatory complexity systematically.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Cision
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Startupticker.ch
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb.com
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old